The projected revenue shortfall for 23andMe in FY24 compared to analyst estimates suggests potential challenges ahead for the company. This news is likely to negatively impact investor sentiment in the short term, as revenue forecasts are a critical indicator of a company's future growth and financial health. The significant difference between the company's forecast and the analysts' expectations could lead to a decrease in stock price as investors adjust their expectations.